
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rinatabart Sesutecan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Rinatabart Sesutecan Shows Promising Anti-Tumor Activity in Ovarian and Endometrial Cancer
Details : Rina-S (rinatabart sesutecan) is an investigational FRα-targeted, Topo1 ADC, which is being evaluated for FR alpha-expressing ovarian cancer, endometrial cancer, primary peritoneal carcinoma.
Product Name : Rina-S
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 15, 2024
Lead Product(s) : Rinatabart Sesutecan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rinatabart Sesutecan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Genmab
Deal Size : $1,800.0 million
Deal Type : Acquisition
Genmab Completes Acquisition of ProfoundBio
Details : The acquisition grants Genmab worldwide rights to three clinical candidates, including Rina-S (rinatabart sesutecan), an FRα-targeted ADC aimed at treating ovarian and endometrial cancer.
Product Name : Rina-S
Product Type : Antibody-drug Conjugate
Upfront Cash : $1,800.0 million
May 21, 2024
Lead Product(s) : Rinatabart Sesutecan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Genmab
Deal Size : $1,800.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rinatabart Sesutecan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Genmab
Deal Size : $1,800.0 million
Deal Type : Acquisition
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Details : Genmab acquires worldwide rights to PRO1184 (rinatabart sesutecan) for treating FRα-expressing platinum-resistant ovarian cancer and two other clinical candidates.
Product Name : Rina-S
Product Type : Antibody-drug Conjugate
Upfront Cash : $1,800.0 million
April 03, 2024
Lead Product(s) : Rinatabart Sesutecan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Genmab
Deal Size : $1,800.0 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rinatabart Sesutecan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ally Bridge Group
Deal Size : $112.0 million
Deal Type : Series B Financing
ProfoundBio Raises $112M in Series B Financing to Advance ADC Pipeline
Details : The financing aims to support the development of ProfoundBio's PRO1184 (rinatabart sesutecan), which is a FRα-targeted ADC being developed for patients with ovarian and endometrial cancer.
Product Name : Rina-S
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
February 13, 2024
Lead Product(s) : Rinatabart Sesutecan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ally Bridge Group
Deal Size : $112.0 million
Deal Type : Series B Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PRO1107
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ProfoundBio Doses First Patient in Phase 1/2 Trial of PRO1107, a PTK7-Targeted ADC
Details : PRO1107 is an ADC targeting PTK7, currently in trials for PTK7-expressing endometrial, ovarian, and triple-negative breast cancers.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2024
Lead Product(s) : PRO1107
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PRO1160
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Details : PRO1160 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 09, 2023
Lead Product(s) : PRO1160
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PRO1184
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRO1184 demonstrates robust anti-tumor activity, is an ADC comprising a folate receptor alpha-directed antibody conjugated to the exatecan payload with ProfoundBio's novel, proprietary hydrophilic linker.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : PRO1184
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PRO1184
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRO1184 is an antibody-drug conjugate comprising a folate receptor alpha (FRa) directed antibody conjugated to an exatecan payload with a novel, proprietary hydrophilic linker.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : PRO1184
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PRO1184
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Sequoia China
Deal Size : $70.0 million
Deal Type : Series A Financing
Details : ProfoundBio will use the proceeds to advance PRO1184 and PRO1160 into Phase 1 clinical trials. PRO1184 is a folate receptor alpha directed ADC for potential treatment of multiple solid tumors and PRO1160 is CD70-directed ADC for both hematological and so...
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
June 02, 2022
Lead Product(s) : PRO1184
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Sequoia China
Deal Size : $70.0 million
Deal Type : Series A Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PRO1184
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Synaffix
Deal Size : $246.0 million
Deal Type : Licensing Agreement
Details : The deal provides access to multiple novel linker-payload technologies developed by Synaffix and includes access to the GlycoConnect™ glycan conjugation and HydraSpace™ polar spacer technologies.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
July 22, 2021
Lead Product(s) : PRO1184
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Synaffix
Deal Size : $246.0 million
Deal Type : Licensing Agreement
